<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Enanta Pharmaceuticals Inc. (ENTA) 是一家专注于病毒感染和免疫疾病的临床阶段生物技术公司，今天将在美国胸科学会 (ATS) 国际会议上重点介绍其研究项目——Zelicapavir 和 EPS-3903。</p>
<p><strong>Zelicapavir</strong> 是一种口服的直接作用抗病毒药物，专门针对 N 蛋白，正在开发用于治疗呼吸道合胞病毒。作为 N 蛋白抑制剂，Zelicapavir 直接干扰病毒的复制能力，而与之相比，融合抑制剂则通过防止细胞被感染来工作，同时允许病毒复制继续进行。</p>
<p>本文是我们优质内容的一部分。请通过 RTTNews 订阅。</p>
<p>立即订阅</p>
<p>已经订阅？请登录</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

Enanta制药

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

医疗业 ETF - Vanguard

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

<p>Enanta 制药公司（ENTA）正在 ATS 国际会议上展示其研究项目 Zelicapavir 和 EPS-3903。Zelicapavir 是一种口服抗病毒药物，针对 N 蛋白用于治疗呼吸道合胞病毒，直接干扰病毒复制</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Enanta Pharmaceuticals Inc. (ENTA), a clinical-stage biotechnology company focusing on viral infections and immunological diseases, will be highlighting its investigational programs - Zelicapavir and EPS-3903 - at the American Thoracic Society (ATS) International Conference today.</p>
<div class="lb-trans"><p>Enanta Pharmaceuticals Inc. (ENTA) 是一家专注于病毒感染和免疫疾病的临床阶段生物技术公司，今天将在美国胸科学会 (ATS) 国际会议上重点介绍其研究项目——Zelicapavir 和 EPS-3903。</p>
</div><p><strong>Zelicapavir</strong>, an oral, direct-acting antiviral specifically targeting the N-protein, is being developed for the treatment of respiratory syncytial virus. As an N-protein inhibitor, Zelicapavir directly disrupts the ability of the virus to replicate, as compared to fusion inhibitors that work by preventing cells from becoming infected while allowing viral replication to continue.</p>
<div class="lb-trans"><p><strong>Zelicapavir</strong> 是一种口服的直接作用抗病毒药物，专门针对 N 蛋白，正在开发用于治疗呼吸道合胞病毒。作为 N 蛋白抑制剂，Zelicapavir 直接干扰病毒的复制能力，而与之相比，融合抑制剂则通过防止细胞被感染来工作，同时允许病毒复制继续进行。</p>
</div><p>This article is part of our premium content offering.Subscribe with a RTTNews subscription.</p>
<div class="lb-trans"><p>本文是我们优质内容的一部分。请通过 RTTNews 订阅。</p>
</div><p>Subscribe Now</p>
<div class="lb-trans"><p>立即订阅</p>
</div><p>Already subscribed? Sign in</p>
<div class="lb-trans"><p>已经订阅？请登录</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

Enanta Pharma's RSV Bet And Immunology Ambitions

rttnews

Enanta 制药在 RSV 领域的投资及其免疫学领域的雄心